Pan-Cancer Analyses Reveal Genomic Features of FOXM1 Overexpression in Cancer

Por Barger, Carter J, Branick, Connor, Chee, Linda, Karpf, Adam R.
Publicado no Cancers (Basel) (2019)

Protein Kinase Cα (PKCα) Is Resistant to Long Term Desensitization/Down-regulation by Prolonged Diacylglycerol Stimulation

Por Lum, Michelle A., Barger, Carter J., Hsu, Alice H., Leontieva, Olga V., Black, Adrian R., Black, Jennifer D.
Publicado no J Biol Chem (2016)

DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer

Por Zhang, Wa, Barger, Carter J, Link, Petra A, Mhawech-Fauceglia, Paulette, Miller, Austin, Akers, Stacey N, Odunsi, Kunle, Karpf, Adam R
Publicado no Epigenetics (2015)

Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression

Por Barger, Carter J., Zhang, Wa, Hillman, Joanna, Stablewski, Aimee B., Higgins, Michael J., Vanderhyden, Barbara C., Odunsi, Kunle, Karpf, Adam R.
Publicado no Oncotarget (2015)

Global DNA Hypomethylation in Epithelial Ovarian Cancer: Passive Demethylation and Association with Genomic Instability

Por Zhang, Wa, Klinkebiel, David, Barger, Carter J., Pandey, Sanjit, Guda, Chittibabu, Miller, Austin, Akers, Stacey N., Odunsi, Kunle, Karpf, Adam R.
Publicado no Cancers (Basel) (2020)

PRAME expression and promoter hypomethylation in epithelial ovarian cancer

Por Zhang, Wa, Barger, Carter J., Eng, Kevin H., Klinkebiel, David, Link, Petra A., Omilian, Angela, Bshara, Wiam, Odunsi, Kunle, Karpf, Adam R.
Publicado no Oncotarget (2016)

NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma

Por Haque, Moinul, Li, Jing, Huang, Yung-Hsing, Almowaled, Meaad, Barger, Carter J., Karpf, Adam R., Wang, Peng, Chen, Will, Turner, Suzanne D., Lai, Raymond
Publicado no Cancers (Basel) (2019)

Expression of the POTE gene family in human ovarian cancer

Por Barger, Carter J, Zhang, Wa, Sharma, Ashok, Chee, Linda, James, Smitha R., Kufel, Christina N., Miller, Austin, Meza, Jane, Drapkin, Ronny, Odunsi, Kunle, Klinkebiel, David, Karpf, Adam R.
Publicado no Sci Rep (2018)

CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax

Por Kour, Smit, Rana, Sandeep, Contreras, Jacob I., King, Hannah M., Robb, Caroline M., Sonawane, Yogesh A., Bendjennat, Mourad, Crawford, Ayrianne J., Barger, Carter J., Kizhake, Smitha, Luo, Xu, Hollingsworth, Michael A., Natarajan, Amarnath
Publicado no Mol Pharmacol (2019)

BORIS expression in ovarian cancer precursor cells alters the CTCF cistrome and enhances invasiveness through GALNT14

Por Hillman, Joanna C., Pugacheva, Elena M., Barger, Carter J., Sribenja, Sirinapa, Rosario, Spencer, Albahrani, Mustafa, Truskinovsky, Alexander M., Stablewski, Aimee, Liu, Song, Loukinov, Dmitri I., Zentner, Gabriel E., Lobanenkov, Victor V., Karpf, Adam R., Higgins, Michael J.
Publicado no Mol Cancer Res (2019)

Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy

Por Robb, Caroline M., Kour, Smit, Contreras, Jacob I., Agarwal, Ekta, Barger, Carter J., Rana, Sandeep, Sonawane, Yogesh, Neilsen, Beth K., Taylor, Margaret, Kizhake, Smitha, Thakare, Rhishikesh N., Chowdhury, Sanjib, Wang, Jing, Black, Jennifer D., Hollingsworth, Michael A., Brattain, Michael G., Natarajan, Amarnath
Publicado no Oncotarget (2017)

Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy

Por Robb, Caroline M., Kour, Smit, Contreras, Jacob I., Agarwal, Ekta, Barger, Carter J., Rana, Sandeep, Sonawane, Yogesh, Neilsen, Beth K., Taylor, Margaret, Kizhake, Smitha, Thakare, Rhishikesh N., Chowdhury, Sanjib, Wang, Jing, Black, Jennifer D., Hollingsworth, Michael A., Brattain, Michael G., Natarajan, Amarnath
Publicado no Oncotarget (2020)